Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: A cohort study

The Lancet Oncology

Volumn 12, Issue 1, 2011, Pages 49-55

  Kempers, Marlies J E ^a   Kuiper, Roland P ^a   Ockeloen, Charlotte W ^a   Chappuis, Pierre O ^b   Hutter, Pierre ^c   Rahner, Nils ^d   Schackert, Hans K ^g   Steinke, Verena ^d   Holinski Feder, Elke ^e   Morak, Monika ^e   Kloor, Matthias ^f   Büttner, Reinhard ^d   Verwiel, Eugene T P ^a   van Krieken, J Han ^a   Nagtegaal, Iris D ^a   Goossens, Monique ^a   van der Post, Rachel S ^a   Niessen, Renée C ^h   Sijmons, Rolf H ^h   Kluijt, Irma ⁱ   Hogervorst, Frans B L ⁱ   Leter, Edward M ^j   Gille, Johan J P ^j   Aalfs, Cora M ^k   Redeker, Egbert J W ^k   Hes, Frederik J ^l   Tops, Carli M J ^l   van Nesselrooij, Bernadette P M ^m   van Gijn, Marielle E ^m   García, Encarna B Gómez ⁿ   Eccles, Diana M ^p   Bunyan, David J ^o   Syngal, Sapna ^q   Stoffel, Elena M ^q   Culver, Julie O ^r   Palomares, Melanie R ^r   Graham, Tracy ^s   Velsher, Lea ^s   Papp, Janos ^t   Oláh, Edith ^t   Chan, Tsun L ^u   Leung, Suet Y ^u   van Kessel, Ad Geurts ^a   Kiemeney, Lambertus A L M ^a   Hoogerbrugge, Nicoline ^a   Ligtenberg, Marjolijn J L ^a   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c Institut Central des Hopitaux Valaisans   (Switzerland)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ NETHERLANDS CANCER INSTITUTE   (Netherlands)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF AMSTERDAM   (Netherlands)

^l LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^m Department of Medical Genetics ^*  (Netherlands)

ⁿ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^o SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^p UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^q DANA FARBER CANCER INSTITUTE   (United States)

^r CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^s DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^t NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^u UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DUODENUM CANCER; ENDOMETRIUM CANCER; FAMILY STUDY; FEMALE; GENE DELETION; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HETEROZYGOTE DETECTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PANCREAS CANCER; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; COHORT STUDIES; COLORECTAL NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE DELETION; HUMANS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; PROMOTER REGIONS, GENETIC; RISK; SEQUENCE DELETION;

EID: 78650692633     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70265-5     Document Type: Article

References (33)

1. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 2009, 76:1-18.
2. Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004, 127:17-25.
3. Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007, 44:353-362.
4. Koornstra JJ, Mourits MJ, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol 2009, 10:400-408.
5. van der Post RS, Kiemeney LA, Ligtenberg MJ, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010, 47:464-470.
6. Ligtenberg MJ, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet 2009, 41:112-117.
7. Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat 2009, 30:197-203.
8. Visvader JE, Lindeman GJ Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
9. Todaro M, Francipane MG, Medema JP, Stassi G Colon cancer stem cells: promise of targeted therapy. Gastroenterology 2010, 138:2151-2162.
10. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004, 23:5748-5758.
11. Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997, 139:1337-1348.
12. Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 2009, 48:737-744.
13. Nagasaka T, Rhees J, Kloor M, et al. Somatic hypermethylation of MSH2 is a frequent event in Lynch syndrome colorectal cancers. Cancer Res 2010, 70:3098-3108.
14. van der Klift H, Wijnen J, Wagner A, et al. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC). Genes Chromosomes Cancer 2005, 44:123-138.
15. Guarinos C, Castillejo A, Barbera VM, et al. EPCAM germ line deletions as causes of Lynch syndrome in Spanish patients. J Mol Diagn 2010, 12:765-770.
16. Chan TL, Yuen ST, Kong CK, et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 2006, 38:1178-1183.
17. Kiemeney LA, Lemmers FA, Verhoeven RH, et al. The risk of cancer in the Netherlands. Ned Tijdschr Geneeskd 2008, 152:2233-2241.
18. Association of Comprehensive Cancer Centres (ACCC), The Netherlands. (accessed Oct 25, 2010). http://www.ikcnet.nl/page.php?id=2616&nav_id=114.
19. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI). (accessed Oct 25, 2010). http://www.seer.cancer.gov/faststats/selections.php?series=cancerData.
20. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology 2009, 137:1621-1627.
21. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996, 110:1020-1027.
22. Ramsoekh D, Wagner A, van Leerdam ME, et al. Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. Hered Cancer Clin Pract 2009, 7:17.
23. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009, 75:141-149.
24. Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 2010, 102:193-201.
25. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009, 302:1790-1795.
26. Koornstra JJ, Kleibeuker JH, Vasen HF Small-bowel cancer in Lynch syndrome: is it time for surveillance?. Lancet Oncol 2008, 9:901-905.
27. Scherer SJ, Seib T, Seitz G, Dooley S, Welter C Isolation and characterization of the human mismatch repair gene hMSH2 promoter region. Hum Genet 1996, 97:114-116.
28. Iwahashi Y, Ito E, Yanagisawa Y, et al. Promoter analysis of the human mismatch repair gene hMSH2. Gene 1998, 213:141-147.
29. Public chromatin-state map Broad/MGH ENCODE group, (accessed June 28, 2010). http://genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=173549417&c=chr2&g=wgEncodeBroadChipSeq.
30. Mendenhall EM, Bernstein BE Chromatin state maps: new technologies, new insights. Curr Opin Genet Dev 2008, 18:109-115.
31. Bernstein BE, Kamal M, Lindblad-Toh K, et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 2005, 120:169-181.
32. Eissenberg JC, Shilatifard A Histone H3 lysine 4 (H3K4) methylation in development and differentiation. Dev Biol 2010, 339:240-249.
33. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 2008, 123:444-449.